Unkategorisiert

PAION Pharma nimmt BYFAVO® (Remimazolam) zum 1. September 2026 aus dem deutschen Markt zurück. Im Rahmen der Erstattungsbetragsverhandlungen mit dem GKV-Spitzenverband […]

We believe responsibility starts locally. That’s why we are delighted to support the Hap Ki Do European Championship 2026 on

Our Managing Director Tilmann Bur was interviewed by ISICEM at this year’s ISICEM Congress. In the interview, he shares insights

We have been a supporting member of the Paul-Ehrlich-Gesellschaft für Infektionstherapie e. V. (PEG) since the beginning of 2026. The

PAION Pharma launched Byfavo® with the active ingredient remimazolam in Germany on January 1, 2026. New active ingredients are a

Since January 1, 2026, PAION Pharma has been a cooperating member of the German Society for Internal Intensive Care and